Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this disease
Description of the Study:
- Title: Randomised, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs.
- Principal Investigator: Salvador Augustin.
- Centres of Implementation: Hospital Universitari Vall d’Hebron.
- Study Population: 290 individuals aged 18-80 years with severe COVID-19 pneumonia.
- Study Type: Randomised, controlled, open, one-site clinical trial.
- Methods: The drugs to be evaluated in this trial are:
– Sandimmun concentrate for solution for infusion (intravenous route), the active substance of which is Cyclosporine.
– Sandimmun soft capsule (oral route), the active substance of which is Cyclosporine.
– Roactemra concentrate for solution for infusion (intravenous route), the active substance of which is Tocilizumab.
Objectives of the Study:
Principal Objective: To assess the mortality impact at 28 days of an immunomodulatory strategy with 2 treatment regimens stratified according to IL-6 plasma levels, administered in addition to standard treatment, in adult patients with severe COVID-19 pneumonia.
Secondary Objective: To assess the impact of this strategy on the following variables: premature mortality (48 hours, 7 days and at hospital), mortality at intensive care unit, days of mechanical ventilation, virus clearance (viral clearance / viral shedding), time to normalization of oxygen saturation , time to defervescence (fever reduction), improvement of inflammatory reaction, days of hospitalization, days of intubation, safety and tolerability of the intervention
More about this Study:
Rationale: The aim is to study the response of patients with severe COVID-19 pneumonia to an immunomodulatory strategy with 2 treatment regimens stratified according to plasma IL-6 levels administered in addition to standard treatment aimed at reducing the inflammatory/immunological response and obtaining a therapeutic benefit in these patients. Positive results could help define the standard treatment of severe COVID-19 pneumonia and have a dramatic impact on both local and global morbidity and mortality. Negative results would also constitute useful scientific evidence to abandon unsubstantiated empirical approaches and help redirect/prioritise resources and efforts in other more promising directions.
Other Studies about Pharmacology:
This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.
CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.
This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID.
Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.
This study suggests that primary care diagnosis and treatment with antihistamines, plus azithromycin in selected cases, may treat COVID-19 and prevent progression to severe disease in elderly patients.
This study aims to evaluate in clinical practice the efficacy and safety of remdesivir in patients admitted for COVID-19.
This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.
Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19.